ArticleBMJ open2018
Article in BMJ open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05731427 (Research on the Mechanism Affecting Progression of Bronchiectasis Based on Omics Method), which is not on this map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Research on the Mechanism Affecting Progression of Bronchiectasis Based on Omics Method
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Psychometrics of health-related quality of life questionnaires in bronchiectasis: a systematic review and meta-analysis.The European respiratory journal · 2021Pooled it
- Treatable traits-based management of bronchiectasis: moving from theory to clinical practice.Chinese medical journal pulmonary and critical care medicine · 2026Review
- Analysis of clinical characteristics and bronchoalveolar lavage fluid microbial community diversity in non-cystic fibrosis bronchiectasis patients withMicrobiology spectrum · 2026Article
- Epidemiological insights into Haemophilus influenzae and Pseudomonas aeruginosa persistent colonization in non-cystic fibrosis bronchiectasis patients: a longitudinal and multicenter study.Respiratory research · 2026Article
- Genomic diversity and adaptive resistance mechanisms inmSystems · 2026Article
- Therapies for bronchiectasis: mechanisms and potential effects.Frontiers in immunology · 2026Review
- Co-infection withFrontiers in medicine · 2026Review
- Anxiety, depression, physical disease parameters and health-related quality of life in the BronchUK national bronchiectasis cohort.ERJ open research · 2025Article
- Comparative efficacy and safety of inhaled antibiotics in managing chronicJournal of thoracic disease · 2025Article
- Article
- Relation between vitamin D deficiency and Pseudomonas aeruginosa colonization in patients with bronchiectasis.BMC pulmonary medicine · 2025Article
- NLRP3 Inflammasome Activation Modulates Neutrophil Extracellular Trap Formation and Aggravates Airway Inflammation in Bronchiectasis.Research (Washington, D.C.) · 2025Article
- Potential Microorganisms from Bronchial Lavage Fluid in Bronchiectasis Patients: Bacteria, Nontuberculous Mycobacteria, and Fungi.The open respiratory medicine journal · 2025Article
- Cost-effectiveness analysis of two inhaled antibiotics for stable Bronchiectasis with Pseudomonas aeruginosa infections in China.PloS one · 2025Article
- Molecular basis for the transcriptional regulation of an epoxide-based virulence circuit in Pseudomonas aeruginosa.Nucleic acids research · 2024Article
- Bronchiectasis in Asia: a review of current status and challenges.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Molecular basis for the transcriptional regulation of an epoxide-based virulence circuit inbioRxiv : the preprint server for biology · 2024Article
- A phase 4 multicentre, 2×2 factorial randomised, double-blind, placebo-controlled trial to investigate the efficacy and safety of tobramycin inhalation solution forERJ open research · 2024Article
- Deciphering the microbial landscape of lower respiratory tract infections: insights from metagenomics and machine learning.Frontiers in cellular and infection microbiology · 2024Article
- Pseudomonas aeruginosa isolation is an important predictor for recurrent hemoptysis after bronchial artery embolization in patients with idiopathic bronchiectasis: a multicenter cohort study.Respiratory research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectives
methodsThis retrospective and follow-up study enrolled 1188 patients diagnosed with bronchiectasis at Shanghai Pulmonary Hospital between January 2011 and December 2012. The patients' clinical data including anthropometry, clinical symptoms, serum biomarkers, radiographic manifestations and lung function indices were reviewed. The median follow-up duration (IQR) was 44 (40-54) months, during which 289 patients were lost to follow-up. Data from 899 patients were collected and analysed for the outcomes of mortality, annual exacerbation frequency and health-related quality of life.
results
conclusionsIsolation of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.